Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

EJNMMI Research

Table 1 Patients’ clinical characteristics and treatment response

Patient	Age/sex	ISS-WM*	M-protein type	IgM (g/L)	M-protein (g/L)	β2-MG (mg/L)	Involvement at baseline	Chemotherapy regimens^a (cycles)	Clinical response^†
1	61/M	Intermediate	IgMκ	30.49	18.5	6.13	BM, LN, PMD, nerve root	R-FC(5) + R-DC(1)	CR
2	72/M	High	IgMκ	5.78	2.1	8.93	BM, LN	DRC(7)	PR
3	72/M	Intermediate	IgMλ	15.2	10.5	3.27	BM	DRC(6)	VGPR
4	64/M	Intermediate	IgMλ	23.69	10.6	5.71	BM, LN	BRD(6)	CR
5	64/M	Intermediate	IgMκ	53.3	32.5	5.27	BM, LN	DRC(8)	VGPR
6	48/F	N/A	IgDκ	6.67(IgD)^‡	6.67	N/A	BM, LN	DRC(6)	PR
7	55/F	Low	IgMκ	82.49	35.6	2.93	BM, LN	DRC(1) + BRD(4) + BD(1)	PR
8	52/F	Intermediate	IgMκ	38.13	21.6	3.34	BM, spleen	DRC(6)	PR
9	58/M	Intermediate	IgMκ	43.48	27.9	12.6	BM, LN, liver, pancreas, PMD	R2(5)	PR
10	48/M	Intermediate	IgMλ	50.9	32.5	6	BM, LN, liver, PMD	DRC(6)	PD
11	62/M	High	IgMκ	33.42	23.7	6	BM, LN	DRC(4)	VGPR
12	76/M	High	IgMλ	96.02	62.8	3.6	BM, LN	BRD(8)	PR
13	53/M	Intermediate	IgMλ	79.89	56.5	3.5	BM, LN, spleen	Chlorambucil(2) + BCD(5)	MR
14	64/M	Intermediate	IgMλ	52.73	30.6	5.9	BM, LN	BRD(4) + DRC(2)	PR
15	64/M	Intermediate	IgMκ	7.57	3.6	3.5	BM	Chlorambucil(5)	PD

β2-MG β2-microglobulin, BM bone marrow, LN lymph node, PMD paramedullary disease
*International Staging System for WM (ISS-WM) prognostic scoring includes age of > 65 y, ß2-microglobulin level of > 3 mg/L, hemoglobin level of ≤ 11.5 g/dL, platelet count of ≤ 100 × 10⁹/L, and IgM level of > 7 g/dL
^‡Serum IgD level was measured as IgD-type M-protein level
^†CR complete response, VGPR very good partial response, PR partial response, MR minimal response, SD stable disease, PD progressive disease
^aR rituximab, D dexamethasone, C cyclophosphamide, B bortezomib, F fludarabine, R2 lenalidomide plus rituximab